SCHEMBL379160

SCHEMBL379160

O=C(OCc1ccccc1)N1CC1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.76
▸ KMT2A Q03164 1/20 0.76
▸ NPSR1 Q6W5P4 1/20 0.76
▸ SMN1; SMN2 Q16637 4/20 0.73
▸ NPC1 O15118 4/20 0.73
▸ RAB9A P51151 4/20 0.73
▸ CYP2C19 P33261 2/20 0.69
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ GRIN2B Q13224 3/20 0.57
▸ HTT P42858 1/20 0.57
▸ CYP2D6 P10635 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ GAA P10253 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ P2RX4 Q99571 1/20 0.54
▸ HTR2C P28335 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4814264 1.00 MEN1 (0.76) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL3970912 1.00 MEN1 (0.76) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL7393652 1.00 MEN1 (0.76) MEN1KMT2ANPSR1SMN1; SMN2NPC1
Bicarbonate SCHEMBL4357688 0.98 MEN1 (0.73) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL15011579 0.98 MEN1 (0.73) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL16611411 0.95 MEN1 (0.69) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL3795583 0.95 MEN1 (0.69) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL7655432 0.93 MEN1 (0.68) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL7658562 0.93 L3MBTL1 (0.68) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL5109854 0.93 MEN1 (0.71) MEN1KMT2ANPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543975-A1 STABILISER COMPOSITION, USE OF THE STABILISER COMPOSITION, METHOD FOR STABILISING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILISED COMPOSITION AND MOULDING OR MOULDED PART CONSISTING THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2025-04-30 — — EP claimed
US-20240182683-A1 STABILIZER COMPOSITION, USE OF THE STABILIZER COMPOSITION, METHOD FOR STABILIZING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILIZED COMPOSITION AND MOLDING OR MOLDED PART CONSISTING THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-06-06 — — US claimed
EP-4308642-A1 STABILIZER COMPOSITION, USE OF THE STABILIZER COMPOSITION, METHOD FOR STABILIZING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILIZED COMPOSITION AND MOLDING OR MOLDED PART CONSISTING THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-01-24 — — EP claimed
WO-2024002610-A1 STABILISER COMPOSITION, USE OF THE STABILISER COMPOSITION, METHOD FOR STABILISING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILISED COMPOSITION AND MOULDING OR MOULDED PART CONSISTING THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-01-04 — — WO claimed
CN-117015566-A Stabilizer composition, use of a stabilizer composition, method for stabilizing polycondensates against hydrolytic degradation, and hydrolytically stable compositions and mouldings or mouldings thereof 弗劳恩霍夫应用研究促进协会 2023-11-07 — — CN claimed
WO-2022195041-A1 STABILIZER COMPOSITION, USE OF THE STABILIZER COMPOSITION, METHOD FOR STABILIZING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILIZED COMPOSITION AND MOLDING OR MOLDED PART CONSISTING THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2022-09-22 — — WO claimed
EP-4658667-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY Merck Sharp & Dohme LLC (US) 2025-12-10 — — EP disclosed
US-12440706-B2 Conjugated chemical inducers of degradation and methods of use GENENTECH, INC. (US) 2025-10-14 — — US disclosed
EP-4543975-A1 STABILISER COMPOSITION, USE OF THE STABILISER COMPOSITION, METHOD FOR STABILISING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILISED COMPOSITION AND MOULDING OR MOULDED PART CONSISTING THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2025-04-30 — — EP disclosed
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC 2024-08-29 — — US disclosed
WO-2024163691-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC (US) 2024-08-08 — — WO disclosed
US-20240182683-A1 STABILIZER COMPOSITION, USE OF THE STABILIZER COMPOSITION, METHOD FOR STABILIZING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILIZED COMPOSITION AND MOLDING OR MOLDED PART CONSISTING THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-06-06 — — US disclosed
EP-4308642-A1 STABILIZER COMPOSITION, USE OF THE STABILIZER COMPOSITION, METHOD FOR STABILIZING CONDENSATION POLYMERS AGAINST HYDROLYTIC DEGRADATION, AND HYDROLYSIS-STABILIZED COMPOSITION AND MOLDING OR MOLDED PART CONSISTING THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-01-24 — — EP disclosed
WO-1997026017-A2 PERFLUOROALKYL-CONTAINING METAL COMPLEXES AND THEIR USE IN NMR DIAGNOSTICS SCHERING AKTIENGESELLSCHAFT (DE) 1997-07-24 — — WO disclosed
WO-1997023245-A1 CASCADE POLYMER COMPLEXES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME SCHERING AKTIENGESELLSCHAFT (DE) 1997-07-03 — — WO disclosed
EP-0768898-A1 CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME SCHERING AKTIENGESELLSCHAFT (DE) 1997-04-23 — — EP disclosed
WO-1997002051-A2 CASCADE POLYMER COMPLEXES SCHERING AKTIENGESELLSCHAFT (DE) 1997-01-23 — — WO disclosed
WO-1996041830-A1 CASCADE POLYMERS WITH IODINE-CONTAINING AROMATIC COMPOUNDS SCHERING AKTIENGESELLSCHAFT (DE) 1996-12-27 — — WO disclosed
WO-1996001655-A1 CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME SCHERING AKTIENGESELLSCHAFT (DE) 1996-01-25 — — WO disclosed
US-4578378-A (Oxoheterocyclic carbonamido)cephem carboxylic acid derivatives SHIONOGI & CO., LTD. (JP) 1986-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY TNF, TNFRSF1A, CD40 MEN1 3591/4885KMT2A 4601/4885NPSR1 779/4885
US-12440706-B2 Conjugated chemical inducers of degradation and methods of use ADRM1, SSB, FCER2 MEN1 4419/4885KMT2A 4147/4885NPSR1 4232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback